Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.38 |
| ▸ | HMGCR | P04035 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61021 | 1.00 | PTPN7 (0.38) | PTPN7HMGCRKDM4EALDH1A1HPGD | |
| SCHEMBL12095320 | 0.95 | KDM4E (0.34) | PTPN7HMGCRKDM4EALDH1A1HPGD | |
| SCHEMBL59321 | 0.83 | — | — | |
| SCHEMBL28334123 | 0.82 | PTPN7 (0.50) | PTPN7HMGCRKDM4EALDH1A1HPGD | |
| SCHEMBL10725642 | 0.79 | HMGCR (0.39) | PTPN7HMGCRKDM4EALDH1A1HPGD | |
| SCHEMBL17537230 | 0.78 | TSHR (0.42) | TSHRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL17537167 | 0.78 | TSHR (0.42) | TSHRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL10985797 | 0.78 | TSHR (0.42) | TSHRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6319883 | 0.78 | PTPN7 (0.47) | PTPN7HMGCRKDM4EALDH1A1HPGD | |
| SCHEMBL8620128 | 0.77 | FAAH (0.52) | PTPN7RECQLTDP1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385991-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | PROVID PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| CN-117881678-A | Compound with SHP2 protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4112053-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308585-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | Provid Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| WO-2024005556-A1 | Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases | VASTHERA CO., LTD. (KR) | 2024-01-04 | — | — | WO | disclosed |
| US-20230286934-A1 | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4161922-A1 | USE OF MULTI-KINASE INHIBITORS TO TREAT RNA VIRUS INFECTIONS | Icahn School of Medicine at Mount Sinai (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2004009609-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009610-A2 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2004004774-A2 | COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA | ESPERION THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004002983-A2 | THERAPEUTIC PIPERAZINE DERIVATIVES USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158439-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II HLA-DRB1*15:01 MOLECULES WITH ENHANCED METABOLIC STABILITY | HLA-DRB1, HLA-B, HLA-C | PTPN7 1436/4885HMGCR 2412/4885KDM4E 3390/4885 |
| US-20230286934-A1 | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections | EIF2AK2, SARS1, ACE2 | PTPN7 2342/4885HMGCR 2746/4885KDM4E 1609/4885 |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | PTPN7 925/4885HMGCR 234/4885KDM4E 2822/4885 |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | CASP5, NLRP3, LITAF | PTPN7 2341/4885HMGCR 611/4885KDM4E 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.